Enhancing efficacy of BH3 mimetics to induce apoptosis in lethal prostate cancer

Ended Project Grant Awarded Last action

Award ID
HT94252410452
Recipient
Awarding agency
Obligated
$299,999

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Great Britain, United Kingdom

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a subawardee, the Institute of Cancer Research has previously partnered with The Washington University on federal grants from this program to adapt medical imaging software, develop annotation frameworks for training cancer detection AI models, and implement support for additional radiotherapy data modalities to enable translational cancer research.

Quick answers

Who received award HT94252410452?

HT94252410452 was awarded to Institute Of Cancer Research: Royal Cancer Hospital (The) by Defense Health Agency (Department of Defense) on June 1, 2024.

How much is award HT94252410452 worth?

$299,999 has been obligated on HT94252410452.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login